Drugs / Assigned dose level of SS1(dsFv)PE38 on days 1, 3 \& 5 of a 21 day cycle for 2 cycles
Assigned dose level of SS1(dsFv)PE38 on days 1, 3 \& 5 of a 21 day cycle for 2 cycles
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01445392 | Nov 2007 → Jan 2014 | mesothelioma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Assigned dose level of SS1(dsFv)PE38 on days 1, 3 \& 5 of a 21 day cycle for 2 cycles | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01445392 ↗ |
| Known as | SS1P | “SS1P (dsFv) PE38, is a recombinant immunotoxin targeting the tumor antigen mesothelin that is highly expressed in malignant mesothelioma.” NCT01445392 ↗ |
| Known as | SS1P (dsFv) PE38 | “SS1P (dsFv) PE38, is a recombinant immunotoxin targeting the tumor antigen mesothelin that is highly expressed in malignant mesothelioma.” NCT01445392 ↗ |
| Action | Deplete | “allowing the toxin to enter and kill the cells.” NCT01445392 ↗ |
| Modality | Protein / enzyme biologic | “SS1P (dsFv) PE38, is a recombinant immunotoxin targeting the tumor antigen mesothelin” NCT01445392 ↗ |
| Route | Intravenous | “Intravenous infusion of SS1(dsFv)PE38.” NCT01445392 ↗ |